| 1433 |
National Cancer Institute |
Html |
en |
Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the genetics of breast and gynecologic cancers, including information about specific genes and family cancer syndromes. The summary also contains information about interventions that may influence the risk of developing breast and gynecologic cancers in individuals who may be genetically susceptible to these diseases. Psychosocial issues associated with genetic testing are also discussed. |
| Pregnancy-associated breast cancer | 0.506333 |
| total breast cancer | 0.488298 |
| primary breast cancer | 0.498056 |
| BRCA1 pathogenic variants | 0.493823 |
| Prospective breast cancer | 0.487994 |
| Br J Cancer | 0.484038 |
| Int J Cancer | 0.495039 |
| individual breast cancer | 0.489704 |
| cancer risk reduction | 0.475227 |
| triple-negative breast cancer | 0.516988 |
| breast cancer decline | 0.488175 |
| ovarian cancer | 0.654478 |
| breast cancer patients | 0.493005 |
| postmenopausal breast cancer | 0.500017 |
| breast cancer risk. | 0.510237 |
| cancer risk assessment | 0.501046 |
| Natl Cancer Inst | 0.80311 |
| Ovarian Cancer Group | 0.476381 |
| BRCA1-associated breast cancer | 0.507407 |
| invasive breast cancer | 0.506617 |
| endometrial cancer | 0.505116 |
| hormone replacement therapy | 0.500252 |
| breast cancer prediction | 0.489793 |
| et al. | 0.567541 |
| BRCA2 mutation carriers | 0.531322 |
|
| women | 0.515983 |
| contralateral breast cancer | 0.498075 |
| early breast cancer | 0.50631 |
| early-onset breast cancer | 0.489583 |
| nonpolyposis colorectal cancer | 0.483231 |
| breast cancer family | 0.518542 |
| breast cancer diagnosis | 0.495632 |
| BOADICEA breast cancer | 0.48834 |
| PUBMED Abstract | 0.498618 |
| pathogenic variants | 0.552407 |
| Cancer Res Treat | 0.576792 |
| Breast Cancer Treatment | 0.508531 |
| epithelial ovarian cancer | 0.48165 |
| ovarian cancer risk | 0.536184 |
| breast cancer risk | 0.765155 |
| Abstract | 0.613814 |
| breast cancer survival | 0.499805 |
| breast cancer | 0.946746 |
| breast cancer mortality | 0.506691 |
| Breast cancer cluster | 0.487434 |
| family history | 0.570688 |
| breast cancer incidence | 0.492239 |
| familial breast cancer | 0.49066 |
| Breast Cancer Res | 0.640001 |
|
CLICK HERE |
| 1456 |
National Cancer Institute |
Html |
en |
Vulvar Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of vulvar cancer. |
| lesion-type VIN grade | 0.488217 |
| radiation therapy arm | 0.777718 |
| vulvar surgical procedures | 0.466679 |
| sentinel node dissection | 0.727156 |
| Radiation Therapy section | 0.586061 |
| case series | 0.468674 |
| groin dissection study | 0.616489 |
| vulvar cancer | 0.538035 |
| positive sentinel nodes | 0.479331 |
| lymph node dissection | 0.680638 |
| sentinel node identification. | 0.538816 |
| invasive vulvar cancer | 0.471336 |
| vulvar cancer-related deaths | 0.462293 |
| radiation therapy issue | 0.483522 |
| clinically localized vulvar | 0.482117 |
| node dissection | 0.932807 |
| bloc inguinal node | 0.506403 |
| sentinel node dissections | 0.642236 |
| bilateral groin node | 0.587002 |
| Actuarial groin recurrence | 0.544605 |
| groin lymph | 0.484094 |
| pelvic node resection | 0.498834 |
| radical vulvectomy | 0.489162 |
| sentinel node | 0.79935 |
|
| high-grade vin | 0.507503 |
| bilateral dissection | 0.465866 |
| groin dissection arm | 0.620835 |
| invasive locoregional vulvar | 0.48636 |
| sentinel node procedures | 0.539343 |
| groin recurrence | 0.545931 |
| groin dissection | 0.6467 |
| femoral lymph node | 0.521493 |
| negative sentinel node | 0.528158 |
| negative sentinel nodes | 0.475577 |
| patients | 0.605395 |
| groin-node dissection | 0.464 |
| inguinal node dissection | 0.663124 |
| groin node dissection | 0.784008 |
| ipsilateral inguinal node | 0.504912 |
| pelvic radiation | 0.458909 |
| Node metastases | 0.461128 |
| groin node-positive disease | 0.523738 |
| groin radiation | 0.532254 |
| regional lymph nodes | 0.463891 |
| HPV 6/11-associated vulvar | 0.461386 |
| negative groin nodes | 0.546977 |
| systematic literature review | 0.508112 |
|
CLICK HERE |
| 1553 |
National Cancer Institute |
Html |
en |
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma. |
| cancer treatment | 0.41722 |
| Burkitt-like non-Hodgkin lymphoma | 0.414505 |
| panniculitis-like T-cell lymphoma | 0.407586 |
| mediastinal B-cell lymphoma | 0.477834 |
| type | 0.421123 |
| body | 0.397298 |
| childhood non-hodgkin lymphoma | 0.888605 |
| PDQ cancer information | 0.389516 |
| Non-Hodgkin Lymphoma Treatment | 0.431482 |
| clinical trial search | 0.395907 |
| B-cell non-Hodgkin lymphoma | 0.444319 |
| gamma-delta T-cell lymphoma | 0.40789 |
| clinical trials | 0.596027 |
| large cell lymphoma | 0.576342 |
| peripheral t-cell lymphoma | 0.4403 |
| clinical trial | 0.545942 |
| stem cell transplant | 0.416614 |
| Burkitt lymphoma | 0.412037 |
| anaplastic lymphoma kinase | 0.405034 |
| primary mediastinal b-cell | 0.402494 |
| diffuse large b-cell | 0.419339 |
| lymph nodes | 0.504405 |
| Pediatric-type follicular lymphoma | 0.401311 |
| large B-cell lymphoma | 0.505692 |
|
| radiation therapy | 0.400696 |
| childhood hodgkin lymphoma | 0.422956 |
| treatment | 0.602592 |
| Hodgkin Lymphoma Treatment | 0.428936 |
| cutaneous t-cell lymphoma | 0.531706 |
| cancer cells | 0.482982 |
| Burkitt-like lymphoma /leukemia | 0.41493 |
| HIV-related non-Hodgkin lymphoma | 0.410943 |
| certain gene changes | 0.416336 |
| Adult Non-Hodgkin Lymphoma | 0.452762 |
| recurrent lymphoblastic lymphoma | 0.388804 |
| lymphoblastic lymphoma | 0.418163 |
| follicular lymphoma | 0.416701 |
| combination chemotherapy | 0.479578 |
| non-hodgkin lymphoma | 0.995932 |
| bone marrow | 0.469909 |
| marginal zone lymphoma | 0.455485 |
| cells | 0.53075 |
| cancer clinical trials | 0.407298 |
| lymph node | 0.390457 |
| treatment options | 0.51667 |
| anaplastic large cell | 0.523091 |
| HIV-associated non-Hodgkin lymphoma | 0.431952 |
| cancer | 0.673011 |
|
CLICK HERE |
| 1559 |
National Cancer Institute |
Html |
en |
Endometrial Cancer Screening (PDQ®)–Patient Version |
Expert-reviewed information summary about tests used to detect or screen for endometrial cancer. |
| cancer treatment | 0.561966 |
| Pap test results | 0.564545 |
| ongoing clinical trials | 0.564273 |
| following PDQ summaries | 0.605267 |
| PDQ cancer information | 0.713937 |
| false-negative test result | 0.559289 |
| Uterine Sarcoma Treatment | 0.562863 |
| uterus | 0.565825 |
| Endometrial sampling | 0.614718 |
| clinical trials | 0.686375 |
| test result | 0.59341 |
| transvaginal ultrasound | 0.592257 |
| cancer information summary | 0.653614 |
| clinical trial | 0.570758 |
| test results | 0.593938 |
| breast cancer prevention | 0.577475 |
| false-positive test result | 0.559048 |
| latest published information | 0.566054 |
| PDQ® Screening | 0.557798 |
| NCI’s PDQ | 0.572282 |
| cancer symptoms | 0.57367 |
| NCI PDQ cancer | 0.624163 |
| tests | 0.615659 |
| black women | 0.581998 |
|
| PDQ Screening | 0.598441 |
| treatment | 0.572654 |
| cancer prevention | 0.577647 |
| screening tests | 0.574176 |
| cancer cells | 0.559463 |
| endometrial cancer screening | 0.701539 |
| Cancer Information Service | 0.589993 |
| Prevention Editorial Board | 0.603972 |
| treatment clinical trials | 0.562297 |
| National Cancer Institute | 0.661886 |
| endometrial cancer | 0.979643 |
| PDQ documents | 0.56725 |
| new treatment | 0.567011 |
| Cancer screening trials | 0.628138 |
| Cancer Care page | 0.581539 |
| PDQ database | 0.570002 |
| breast cancer | 0.579583 |
| abnormal vaginal bleeding | 0.663193 |
| non-polyposis colon cancer | 0.588586 |
| risk factor | 0.558033 |
| PDQ summary | 0.615448 |
| yearly screening | 0.56313 |
| cancer information summaries | 0.594869 |
| comprehensive cancer information | 0.595413 |
|
CLICK HERE |
| 1768 |
National Cancer Institute |
Html |
es |
Perjuicios por fumar cigarrillos y beneficios para la salud al dejar el hábito |
Hoja informativa que contiene una lista de algunas de las sustancias del humo de tabaco que causan cáncer y describe los problemas de salud causados por fumar y los beneficios de dejar el hábito. |
| Neck Cancer Epidemiology | 0.422589 |
| Mortality Weekly Report | 0.414031 |
| Human Services | 0.435201 |
| An emerging health | 0.441866 |
| Annual smoking-attributable mortality | 0.414117 |
| National Health Interview | 0.418634 |
| productivity losses—united states | 0.413073 |
| muertes prematuras | 0.445781 |
| Disease Control | 0.419031 |
| tabaco sustancias | 0.451048 |
| emerging health crisis | 0.417693 |
| promoting smoking | 0.427125 |
| Health Benefits | 0.414213 |
| Estados Unidos | 0.436732 |
| Health Behavior | 0.414461 |
| olor. fumar kreteks | 0.444861 |
| smoking cessation after | 0.432247 |
| PubMed Abstract | 0.980608 |
| smoking cessation | 0.497845 |
| Smokeless Tobacco | 0.414167 |
| Second-hand Tobacco Smoke | 0.420375 |
| International Journal | 0.420012 |
| Smoking as | 0.425711 |
| Tobacco Research | 0.428882 |
| United States | 0.434188 |
|
| British Medical Journal | 0.433726 |
| early stage lung | 0.412709 |
| Causa cánceres | 0.417577 |
| causa enfermedades | 0.437169 |
| ambiente causa | 0.426356 |
| tobacco smoking | 0.490331 |
| obstructiva crónica | 0.447997 |
| tobacco aqueous pH | 0.419205 |
| Eissenberg T | 0.417223 |
| ambiente causa enfermedades | 0.423335 |
| causa inflamación | 0.413975 |
| Maziak W | 0.417052 |
| Ward KD | 0.4175 |
| systematic review | 0.417039 |
| muerte prematura | 0.420666 |
| Chronic Disease Prevention | 0.413895 |
| Andrology Prevention Weeks | 0.412666 |
| emerging health risk | 0.421288 |
| Cancer Institute | 0.452427 |
| leucemia mieloide aguda | 0.439669 |
| neck cancer | 0.417125 |
| cuánta nicotina | 0.415037 |
| Public Health Service | 0.416067 |
| New England Journal | 0.413417 |
|
CLICK HERE |
| 1836 |
National Cancer Institute |
Html |
es |
Tratamiento de la leucemia mieloide aguda y otras neoplasias mieloides malignas infantiles (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de la leucemia mieloide aguda infantil, síndromes mielodisplásicos y otras neoplasias mieloproliferativas. |
| frecuencia mutaciones | 0.438095 |
| LMA familiares | 0.551304 |
| leucemia eritroidea aguda | 0.449843 |
| American Academy | 0.418016 |
| Leucemia aguda eritroidea | 0.453243 |
| gen runx1t1 | 0.417024 |
| neoplasias mieloides | 0.421266 |
| transient leukemia | 0.421355 |
| Sin embargo | 0.442991 |
| gen crebbp | 0.417273 |
| LMA ayuda | 0.492779 |
| necesarias mutaciones | 0.436351 |
| leucemia mielomonocÃtica aguda | 0.45265 |
| Panmielosis aguda | 0.424398 |
| subtipo fab | 0.419671 |
| leucemias mieloides | 0.437133 |
| Leucemia basofÃlica aguda | 0.453074 |
| leucemia mielógena | 0.434701 |
| Children's Oncology Group | 0.430324 |
| gen etv6 | 0.41685 |
| leucemia transitoria | 0.433759 |
| reordenamiento leucemia aguda | 0.452795 |
| Leucemia megacarioblástica aguda | 0.453115 |
| Smith MA | 0.431884 |
| Leucemia aguda mielomonocÃtica | 0.453529 |
|
| gen evi1 | 0.417889 |
| leucemia promielocÃtica aguda | 0.56535 |
| Organización Mundial | 0.42957 |
| gen mll | 0.697325 |
| células madre | 0.41719 |
| leucemia aguda | 0.953312 |
| LMA M0 | 0.546818 |
| leucemia linfoblástica aguda | 0.491741 |
| SAI Leucemia | 0.451225 |
| tipo ii | 0.459931 |
| gen runx1 | 0.418208 |
| Pediatr Blood Cancer | 0.433879 |
| gen cbf-beta | 0.418127 |
| M0 LMA | 0.495335 |
| leucemia monocÃtica aguda | 0.501087 |
| fraterno presente leucemia | 0.436812 |
| linaje mieloide | 0.448127 |
| leucemias bifenotÃpicas mieloides | 0.422616 |
| leucemia megacariocÃtica aguda | 0.525006 |
| leucemia mieloblástica aguda | 0.537614 |
| BCR-ABL1 Leucemia aguda | 0.451622 |
| leucemia mieloide aguda | 0.756372 |
| linaje linfoide | 0.423692 |
| La traslocación | 0.522981 |
|
CLICK HERE |
| 1949 |
National Cancer Institute |
Html |
es |
Tratamiento del linfoma relacionado con el sida (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del linfoma relacionado con el sida. |
| linfáticos afectados.ampliar linfoma | 0.30069 |
| estadio iiis+e | 0.227448 |
| células madre | 0.561403 |
| estadio iv | 0.248805 |
| siguientes elementos | 0.21398 |
| sudores nocturnos | 0.287643 |
| alto riesgo | 0.208757 |
| vÃa oral | 0.208173 |
| historial médico | 0.211748 |
| rayos x | 0.210669 |
| abdomen).ampliar linfoma | 0.262027 |
| estadio ie | 0.284505 |
| cáncer.ampliar aspiración | 0.213287 |
| lÃquido cefalorraquÃdeo | 0.384161 |
| punción espinal.Ampliar | 0.212727 |
| National Cancer Institute | 0.208952 |
| Instituto Nacional | 0.215593 |
| estadio iie | 0.283482 |
|
| PDQ Tratamiento | 0.219955 |
| segura medicamentos | 0.210953 |
| lÃquido incoloro | 0.216453 |
| siguientes biopsias | 0.213705 |
| estadio iiie | 0.319333 |
| siguientes problemas | 0.21343 |
| sistema nervioso central | 0.917575 |
| Physician Data Query | 0.232209 |
| cabo actividades | 0.210804 |
| ósea elabora glóbulos | 0.24265 |
| SNC).Ampliar Quimioterapia | 0.221029 |
| estadio iiis | 0.541053 |
| almacena células | 0.232785 |
| células b | 0.231648 |
| Estadio IIIE+S | 0.227106 |
| siguientes pruebas | 0.212565 |
| siguientes estadios | 0.212441 |
|
CLICK HERE |
| 2002 |
National Cancer Institute |
Html |
es |
Tratamiento del feocromocitoma y paraganglioma (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del feocromocitoma y paraganglioma. |
| associated with | 0.440801 |
| paraganglioma hereditario sdhd | 0.442898 |
| Surg Oncol Clin | 0.439027 |
| Gimenez-Roqueplo AP | 0.438768 |
| Chatellier G | 0.438739 |
| patients with apparently | 0.435891 |
| with von hippel-lindau | 0.426826 |
| evaluation following resection | 0.43956 |
| gastric stromal sarcoma | 0.435317 |
| Carney JA | 0.479643 |
| hereditary paraganglioma | 0.424404 |
| gland scaled score | 0.43937 |
| Clin Proc | 0.426209 |
| effective treatment with | 0.472522 |
| secondary hypertension | 0.431368 |
| Neuroendocrine Neoplasias | 0.453768 |
| extra-adrenal paraganglioma | 0.447147 |
| von hippel-lindau | 0.471522 |
| feocromocitoma sÃndrome | 0.499112 |
| patients with | 0.828258 |
| Clin Endocrinol Metab | 0.986823 |
| Young WF Jr | 0.474746 |
| or secreting | 0.439481 |
| Servais A | 0.436374 |
| patients with metastatic | 0.46137 |
|
| Surg Pathol | 0.438013 |
| hypertension persistence after | 0.484322 |
| adrenal gland scaled | 0.443509 |
| Fofol I | 0.439495 |
| Feocromocitoma Opciones estándar | 0.480462 |
| Endocrinol Metab Clin | 0.443246 |
| feocromocitoma metastásico cirugÃa | 0.494173 |
| during pregnancy | 0.424683 |
| feocromocitoma-paraganglioma familiar tipo | 0.517532 |
| Long-term evaluation following | 0.440068 |
| endocrina múltiple tipo | 0.439079 |
| Pacak K | 0.437715 |
| Heerden JA | 0.443555 |
| with combination chemotherapy | 0.426625 |
| Intern Med | 0.453092 |
| autosomal dominant paraganglioma | 0.427278 |
| Clin Oncol | 0.478285 |
| extra suprarrenales surgen | 0.434497 |
| extra suprarrenales | 0.652785 |
| carney triad | 0.424742 |
| feocromocitoma regional cirugÃa | 0.492979 |
| parasimpáticos extra suprarrenales | 0.431253 |
| associated with sdhb | 0.428378 |
| familial paraganglioma | 0.44151 |
|
CLICK HERE |
| 2053 |
National Cancer Institute |
Html |
es |
Vacunas contra los virus del papiloma humano |
Una hoja informativa acerca de las vacunas contra los virus del papiloma humano (VPH) para prevenir infecciones con ciertos tipos de VPH, los cuales son la causa principal del cáncer de cuello del útero o cérvix. |
| HPV prophylactic vaccines | 0.314226 |
| hpv vaccine | 0.332876 |
| Lancet Oncology | 0.308843 |
| with preexisting infection | 0.306342 |
| Mortality Weekly Report | 0.31501 |
| bivalent hpv vaccination | 0.314902 |
| largo plazo | 0.306588 |
| Disease Control | 0.307862 |
| genital warts among | 0.306064 |
| clinical trial | 0.315859 |
| anal hpv | 0.312394 |
| Estados Unidos | 0.376477 |
| hpv vaccination | 0.357231 |
| Hariri S | 0.317621 |
| Rica Vaccine Trial | 0.314539 |
| PubMed Abstract | 0.885463 |
| human papillomavirus | 0.614779 |
| vacunas gardasil® | 0.319024 |
| Infectious Diseases | 0.318629 |
| quadrivalent hpv | 0.312783 |
| Chaturvedi AK | 0.307922 |
| BMC Infectious Diseases | 0.305886 |
| hpv infection | 0.324228 |
| Hildesheim A | 0.314688 |
| Feng Q | 0.308321 |
|
| among young | 0.314298 |
| papillomavirus acquisition | 0.305662 |
| United States | 0.307989 |
| alto riesgo | 0.531462 |
| Updated HPV Vaccination | 0.328083 |
| British Medical Journal | 0.305646 |
| HPV Vaccination Recommendations | 0.328083 |
| Costa Rica | 0.313988 |
| Immunization Practices | 0.308391 |
| Advisory Committee | 0.307786 |
| papillomavirus among | 0.306019 |
| infecciones persistentes. gardasil | 0.336098 |
| 9-valent human papillomavirus | 0.32439 |
| papillomavirus prophylactic vaccines | 0.30978 |
| Bocchini JA | 0.307795 |
| ¿Cuáles cánceres | 0.312957 |
| Hughes JP | 0.308264 |
| bivalent hpv | 0.331056 |
| cuello uterino | 0.992097 |
| Vaccine Safety Datalink | 0.314052 |
| genital hpv infection | 0.315334 |
| Cancer Institute | 0.307587 |
| New England Journal | 0.348895 |
| Petrosky E | 0.307326 |
|
CLICK HERE |
| 15738 |
National Cancer Institute |
Html |
en |
Financial Toxicity and Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the risk of experiencing financial difficulty during cancer treatment. |
| adult cancer survivors | 0.29753 |
| cancer treatment | 0.260149 |
| study | 0.333877 |
| high out-of-pocket spending | 0.29174 |
| health insurance | 0.332995 |
| newly diagnosed cancer | 0.254116 |
| out-of-pocket cost burden | 0.275794 |
| financial hardship | 0.814372 |
| colorectal cancer patients | 0.270243 |
| colorectal cancer survivors | 0.274934 |
| economic burden | 0.33821 |
| higher out-of-pocket spending | 0.308086 |
| Support Care Cancer | 0.263278 |
| material financial hardship | 0.310411 |
| Cancer Care Outcomes | 0.299421 |
| high out-of-pocket costs | 0.25691 |
| health care | 0.364957 |
| out-of-pocket health care | 0.305633 |
| higher out-of-pocket costs | 0.256873 |
| high out-of-pocket burden | 0.326935 |
| State cancer patients | 0.282656 |
| cancer care | 0.417219 |
| personal financial burden | 0.365783 |
| lung cancer patients | 0.262392 |
|
| ongoing cancer care | 0.28258 |
| colorectal cancer | 0.3351 |
| cancer patients | 0.489203 |
| Clin Oncol | 0.334879 |
| comprehensive cancer center | 0.290609 |
| cancer-related financial burden | 0.257868 |
| cancer diagnosis | 0.320181 |
| later financial hardship | 0.252008 |
| Long-term financial burden | 0.276409 |
| financial distress | 0.563858 |
| out-of-pocket spending | 0.410176 |
| breast cancer survivors | 0.328299 |
| financial burden | 0.630038 |
| out-of-pocket costs | 0.285058 |
| greater financial burden | 0.273818 |
| financial toxicity | 0.49873 |
| cancer survivors | 0.880073 |
| advanced-stage cancer patients | 0.289755 |
| high financial burden | 0.284717 |
| cancer | 0.949444 |
| substantial financial hardship | 0.256681 |
| risk | 0.255869 |
| cancer history | 0.289124 |
|
CLICK HERE |